SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern

doi:10.1038/s41392-021-00623-2

Comment

. 2021 May 22;6(1):203.

doi: 10.1038/s41392-021-00623-2.

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern

Ji Yun Noh^#^{1

2}, Hye Won Jeong^#^{2

3}, Eui-Cheol Shin^{4

5}

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
² Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
³ Division of Infectious Diseases, Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
⁴ Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. ecshin@kaist.ac.kr.
⁵ The Center for Epidemic Preparedness, KAIST, Daejeon, Republic of Korea. ecshin@kaist.ac.kr.

^# Contributed equally.

PMID: 34023862
PMCID: PMC8140323
DOI: 10.1038/s41392-021-00623-2

Comment

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern

Ji Yun Noh et al. Signal Transduct Target Ther. 2021.

. 2021 May 22;6(1):203.

doi: 10.1038/s41392-021-00623-2.

Authors

Ji Yun Noh^#^{1

2}, Hye Won Jeong^#^{2

3}, Eui-Cheol Shin^{4

5}

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
² Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
³ Division of Infectious Diseases, Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
⁴ Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. ecshin@kaist.ac.kr.
⁵ The Center for Epidemic Preparedness, KAIST, Daejeon, Republic of Korea. ecshin@kaist.ac.kr.

^# Contributed equally.

PMID: 34023862
PMCID: PMC8140323
DOI: 10.1038/s41392-021-00623-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1**
COVID-19 vaccines elicit SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cell responses as well as neutralizing antibodies. Even though antibodies elicited by current COVID-19 mRNA vaccines had shown diminished neutralizing activities against SARS-CoV-2 variants, T-cell responses may have a role for host protection against SARS-CoV-2 variants

See this image and copyright information in PMC

Comment on

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC. Wang Z, et al. Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10. Nature. 2021. PMID: 33567448 Free PMC article.

Cited by

Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.
Nappi F, Iervolino A, Avtaar Singh SS. Nappi F, et al. Biomedicines. 2022 Feb 14;10(2):437. doi: 10.3390/biomedicines10020437. Biomedicines. 2022. PMID: 35203646 Free PMC article. Review.
Identification of a Potential mRNA-based Vaccine Candidate against the SARS-CoV-2 Spike Glycoprotein: A Reverse Vaccinology Approach.
Durojaye OA, Sedzro DM, Idris MO, Yekeen AA, Fadahunsi AA, Alakanse OS. Durojaye OA, et al. ChemistrySelect. 2022 Feb 18;7(7):e202103903. doi: 10.1002/slct.202103903. Epub 2022 Feb 17. ChemistrySelect. 2022. PMID: 35601809 Free PMC article.
CEBIT screening for inhibitors of the interaction between SARS-CoV-2 spike and ACE2.
Pei G, Xu W, Lan J, Wang X, Li P. Pei G, et al. Fundam Res. 2022 Mar 3;2(4):562-569. doi: 10.1016/j.fmre.2022.01.034. eCollection 2022 Jul. Fundam Res. 2022. PMID: 40477955 Free PMC article.
Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses.
Levy Y, Alcalay R, Zvi A, Makdasi E, Peretz E, Noy-Porat T, Chitlaru T, Mandelboim M, Mazor O, Rosenfeld R. Levy Y, et al. Vaccines (Basel). 2022 Feb 7;10(2):251. doi: 10.3390/vaccines10020251. Vaccines (Basel). 2022. PMID: 35214711 Free PMC article.
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy.
Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, Lowery P, Smith F, Dhanasekaran M, Moore T. Ramesh S, et al. Vaccines (Basel). 2021 Oct 18;9(10):1195. doi: 10.3390/vaccines9101195. Vaccines (Basel). 2021. PMID: 34696303 Free PMC article. Review.

See all "Cited by" articles

References

1. Wang Z, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622. doi: 10.1038/s41586-021-03324-6. - DOI - PMC - PubMed
1. Chen RE, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. doi: 10.1038/s41591-021-01294-w. - DOI - PMC - PubMed
1. Wang P, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135. doi: 10.1038/s41586-021-03398-2. - DOI - PubMed
1. Agerer B, et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses. Sci. Immunol. 2021;6:eabg6461. doi: 10.1126/sciimmunol.abg6461. - DOI - PMC - PubMed
1. Tarke, A. et al. Negligible impact of SARS-CoV-2 variants on CD4+and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. Preprint at bioRxiv10.1101/2021.02.27.433180 (2021).

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Wang Z, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622. doi: 10.1038/s41586-021-03324-6. - DOI - PMC - PubMed

[2] Wang Z, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622. doi: 10.1038/s41586-021-03324-6. - DOI - PMC - PubMed

[3] Chen RE, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. doi: 10.1038/s41591-021-01294-w. - DOI - PMC - PubMed

[4] Chen RE, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. doi: 10.1038/s41591-021-01294-w. - DOI - PMC - PubMed

[5] Wang P, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135. doi: 10.1038/s41586-021-03398-2. - DOI - PubMed

[6] Wang P, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135. doi: 10.1038/s41586-021-03398-2. - DOI - PubMed

[7] Agerer B, et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses. Sci. Immunol. 2021;6:eabg6461. doi: 10.1126/sciimmunol.abg6461. - DOI - PMC - PubMed

[8] Agerer B, et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses. Sci. Immunol. 2021;6:eabg6461. doi: 10.1126/sciimmunol.abg6461. - DOI - PMC - PubMed

[9] Tarke, A. et al. Negligible impact of SARS-CoV-2 variants on CD4+and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. Preprint at bioRxiv10.1101/2021.02.27.433180 (2021).

[10] Tarke, A. et al. Negligible impact of SARS-CoV-2 variants on CD4+and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. Preprint at bioRxiv10.1101/2021.02.27.433180 (2021).

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern

Affiliations

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous